Table 1.

Disease characteristics at baseline and efficacy at Wk 16

PBO N=133BKZ 160 mg Q4W N=267p value
Baseline characteristicsTJCmean (SD)19.3 (14.2)18.4 (13.5)-
SJCmean (SD)10.3 (8.2)9.7 (7.5)-
PtGA-PsAmean (SD)63.0 (22.0)60.5 (22.5)-
PtAAPmean (SD)61.7 (24.6)58.3 (24.2)-
Psoriasis BSAn (%)
<3%45 (33.8)91 (34.1)-
≥3 to ≤10%63 (47.4)109 (40.8)-
>10%25 (18.8)67 (25.1)-
PASIamean (SD)8.5 (6.6)b10.1 (9.1)c-
Prior TNFin (%)
Inadequate response to 1 TNFi103 (77.4)204 (76.4)-
Inadequate response to 2 TNFi15 (11.3)29 (10.9)-
Intolerance to TNFi15 (11.3)34 (12.7)-
Current cDMARDsn (%)63 (47.4)139 (52.1)-
Ranked endpoints in hierarchical orderACR50* [NRI] n (%)9 (6.8)116 (43.4)<0.001
HAQ-DI CfB [RBMI] mean (SE)–0.1 (0.0)–0.4 (0.0)<0.001
PASI90†a [NRI]n (%)6 (6.8)b121 (68.8)c<0.001
SF-36 PCS CfB [RBMI]mean (SE)1.4 (0.7)7.3 (0.5)<0.001
MDA Response [NRI]n (%)8 (6.0)118 (44.2)<0.001
Other endpointsACR20 [NRI]n (%)21 (15.8)179 (67.0)<0.001
ACR70 [NRI] n (%)1 (0.8)71 (26.6)<0.001
TJC CfB [MI] mean (SE)–2.4 (0.9)–10.9 (0.8)<0.001
SJC CfB [MI] mean (SE)–2.0 (0.5)–7.0 (0.4)<0.001
PASI75a [NRI]n (%)9 (10.2)b145 (82.4)c<0.001
PASI100a [NRI]n (%)4 (4.5)b103 (58.5)c<0.001
  • Randomised set (N=400). *Primary endpoint; Secondary endpoint; Nominal p value. aIn patients with ≥3% BSA with PSO at BL; bn=88; cn=176.